SCHEMBL335211

SCHEMBL335211

Nc1nc2ccc(NC(=O)C(O)C(NC(=O)c3ccc(-n4cccc4)cc3)c3ccccc3)cc2[nH]1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 1/20 0.41
FABP6 P51161 1/20 0.41
MAPT P10636 4/20 0.41
MAPK1 P28482 1/20 0.41
ACP1 P24666 1/20 0.39
F9 P00740 1/20 0.38
F7 P08709 1/20 0.38
TYMS P04818 5/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
POLB P06746 3/20 0.37
LMNA P02545 1/20 0.37
CHEK2 O96017 1/20 0.36
KDM4E B2RXH2 1/20 0.35
NPC1 O15118 1/20 0.35
ALDH1A1 P00352 1/20 0.35
RAB9A P51151 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
NR2E3 Q9Y5X4 1/20 0.35
MEN1 O00255 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL336367 0.89 MAPT (0.47) ABL1FABP6MAPTMAPK1ACP1
SCHEMBL335948 0.89 ABL1 (0.45) ABL1FABP6MAPTACP1F9
SCHEMBL335105 0.88 MAPT (0.44) ABL1FABP6MAPTACP1F9
SCHEMBL335878 0.87 ABL1 (0.43) ABL1FABP6MAPTMAPK1ACP1
SCHEMBL335486 0.87 MAPK14 (0.44) MAPTMAPK1ACP1LMNACHEK2
SCHEMBL335576 0.86 ABL1 (0.43) ABL1FABP6MAPTMAPK1ACP1
SCHEMBL336586 0.86 GRIN1 (0.44) ABL1FABP6ACP1F9F7
SCHEMBL8219489 0.86 F9 (0.43) ABL1FABP6MAPTMAPK1ACP1
SCHEMBL335390 0.86 ABL1 (0.44) ABL1FABP6MAPTACP1F9
SCHEMBL334843 0.85 KDR (0.45) ABL1FABP6F9F7TYMS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2069289-B1 ISOSERINE DERIVATIVES FOR USE AS COAGULATION FACTOR IXa INHIBITORS SANOFI SA (FR) 2013-10-02 EP claimed
US-8097758-B2 Isoserine derivatives for use as coagulation factor IXa inhibitors SANOFI-AVENTIS (FR) 2012-01-17 US claimed
US-20090233949-A1 ISOSERINE DERIVATIVES FOR USE AS COAGULATION FACTOR IXA INHIBITORS SANOFI-AVENTIS (FR) 2009-09-17 US claimed
CN-101516834-A Isoserine derivatives for use as coagulation factor ixa inhibitors SANOFI AVENTIS (FR) 2009-08-26 CN claimed
EP-2069289-A1 ISOSERINE DERIVATIVES FOR USE AS COAGULATION FACTOR IXa INHIBITORS Sanofi-Aventis (FR) 2009-06-17 EP claimed
WO-2008031509-A1 ISOSERINE DERIVATIVES FOR USE AS COAGULATION FACTOR IXa INHIBITORS SANOFI-AVENTIS (FR) 2008-03-20 WO claimed
EP-2069289-B1 ISOSERINE DERIVATIVES FOR USE AS COAGULATION FACTOR IXa INHIBITORS SANOFI SA (FR) 2013-10-02 EP disclosed
CN-1359423-A Herbicide resistant plants HINZENTA CO LTD (GB) 2002-07-17 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233949-A1 ISOSERINE DERIVATIVES FOR USE AS COAGULATION FACTOR IXA INHIBITORS TFPI, F2, F9 ABL1 2660/4885FABP6 3044/4885MAPT 3998/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.